Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Doxorubicin + L-DOS47 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Doxorubicin | Adriamycin | Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin | Chemotherapy - Anthracycline 13 TOPO2 inhibitor 5 | Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov). |
L-DOS47 | L DOS47|LDOS47 | CEACAM6 Antibody 3 | L-DOS47 comprises urease linked to a monoclonal antibody that targets CEACAM6, which targets urease to tumors, leading to local conversion of urea to ammonia and increased pH, potentially resulting in cytoxicity in tumor cells (J Thorac Oncol, Vol 12 , Issue 1, S1071-S1072, PMID: 25938892). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04203641 | Phase Ib/II | Doxorubicin + L-DOS47 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | Active, not recruiting | USA | 0 |